Coronary Heart Disease Risk in Type 2 Diabetes

NCT ID: NCT01891786

Last Updated: 2016-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

211 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the CORDIA study is to use an effective evidence-based self-management intervention (SMI) for type 2 diabetes, with and without a novel test to give a personalised genetic and lifestyle risk of coronary heart disease, to examine their capacity to reduce the risk of coronary heart disease (CHD) and improve diabetes management in primary care patients with type 2 diabetes. The effect of these interventions on clinical, behavioural and psychological outcomes will be investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care

The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.

Group Type NO_INTERVENTION

No interventions assigned to this group

Group Self-Management Intervention (SMI)

Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.

Group Type ACTIVE_COMPARATOR

Self-Management Intervention

Intervention Type BEHAVIORAL

The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk

SMI + Risk Results

The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.

Group Type ACTIVE_COMPARATOR

Self-Management Intervention

Intervention Type BEHAVIORAL

The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk

Risk Result

Intervention Type BEHAVIORAL

Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Self-Management Intervention

The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk

Intervention Type BEHAVIORAL

Risk Result

Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females aged 25-70 years diagnosed with type 2 diabetes
* White, Afro-Caribbean or Asian-Indian ethnicity
* Most previous or baseline HbA1c ≥6.5% or 48 mmol/mol
* Fluency in written and spoken English

Exclusion Criteria

* Diagnosis of ischemic heart disease, stroke, Transient Ischaemic Attack (TIA) or peripheral vascular disease
* Serious or enduring mental health problems that would prevent the patient from completing the study
* Currently receiving treatment for a life-threatening condition (e.g., cancer) or in the terminal stages of a condition
* Adults who cannot consent for themselves
Minimum Eligible Age

25 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University College, London

OTHER

Sponsor Role collaborator

City, University of London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stanton Newman

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stanton P Newman, PhD

Role: PRINCIPAL_INVESTIGATOR

City, University of London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Addison House Surgery

Harlow, Essex, United Kingdom

Site Status

Church Street Surgery

Ware, Essex, United Kingdom

Site Status

Dolphin House Surgery

Ware, Essex, United Kingdom

Site Status

Wallace House Surgery

Hertford, Hertfordshire, United Kingdom

Site Status

Cambridgeshire Community Services NHS Trust

Cambridgeshire, , United Kingdom

Site Status

Chesterfield Drive Surgery

Ipswich, , United Kingdom

Site Status

Martlesham health Surgery

Ipswich, , United Kingdom

Site Status

Dr Taylor and Partners

Woodbridge Suffolk, , United Kingdom

Site Status

The Peninsula Practice

Woodbridge Suffolk, , United Kingdom

Site Status

Wickham Market Medical Centre

Woodbridge Suffolk, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Beaney KE, Ward CE, Bappa DA, McGale N, Davies AK, Hirani SP, Li K, Howard P, Vance DR, Crockard MA, Lamont JV, Newman S, Humphries SE. A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. Cardiovasc Diabetol. 2016 Oct 3;15(1):141. doi: 10.1186/s12933-016-0457-7.

Reference Type DERIVED
PMID: 27716211 (View on PubMed)

Davies AK, McGale N, Humphries SE, Hirani SP, Beaney KE, Bappa DA, McCabe JG, Newman SP. Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial. Trials. 2015 Dec 2;16:547. doi: 10.1186/s13063-015-1073-7.

Reference Type DERIVED
PMID: 26631181 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RRMR11-001

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

12/EE/0437

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.